Tracks blood pressure with a wearable device to study heart risk
Studies blood pressure monitoring with a wearable device in adults to find early hypertension.
Plain-language title generated from the registry record
Registry title: Evaluation of the Clinical Benefit of the Aktiia Blood Pressure Monitoring for Early Awareness of Hypertension and Prediction of Cardiovascular Risk
Key facts
- Where
- Lausanne, SwitzerlandSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 21 and 85 years old?
Source: NCT06670677, who can take part
Where in Switzerland
- LausanneLausanne, SwitzerlandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Aktiia SA
- Trial code
- NCT06670677
- Record updated
- 14 May 2025
- Original description
Because Aktiia S.A. has been the first-ever company to put in the market an Optical Blood Pressure Monitoring device, there is a need for Aktiia S.A. to correlate for the first time continual Blood Pressure monitoring and the evolution of environmental and health factors to improve hypertension management.Read full original descriptionShow less
OBPM_FORESEE2024: Evaluation of the Clinical Benefit of the Aktiia Blood Pressure Monitoring for Early Awareness of Hypertension and Prediction of Cardiovascular Risk in a Multi-ethnic European Population: an Observational Cohorts' Study
Because Aktiia S.A. has been the first-ever company to put in the market an Optical Blood Pressure Monitoring device, there is a need for Aktiia S.A. to correlate for the first time continual Blood Pressure monitoring and the evolution of environmental and health factors to improve hypertension management.
Inclusion: Adult subjects aged 21 to 85 years old; Subjects living in Switzerland, Germany or in the UK; Subjects that are:; Aktiia users owning a smartphone with either iOS or Android operating system (ARMs 1 and 2); or Aktiia non-users owning a smartphone with iOS or Android operating system (ARM 3); Subjects agreeing to follow the study procedures.
Exclusion: Subjects suffering from sustained cardiac arrhythmias that can lead to weak or unstable pressure pulses including resting tachycardia (heart rate at rest > 120bpm) and atrial fibrillation; Subjects suffering from pathologies that systematically reduce peripheral perfusion including Raynaud's disease, diabetes, renal dysfunctions (eGFR < 30mL / min / 1.73 m2), untreated hyper-/ hypothyroidism, pheochromocytoma, or arteriovenous fistula; Subjects below 21 years old and above 85 years old; Subjects suffering from polyneuropathy; on pregnant women; Subjects with damaged / injured skin at the wrists (for bracelet measurements) or at index fingers (for camera measurements); Subjects with amputated index fingers (for camera measurements) or amputated upper limb.